Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis. Numerous open-label and, more recently, placebo-controlled trials have documented the efficacy of risperidone in the management of behavioral and psychological symptoms of dementia. These trials also show that risperidone is better tolerated than conventional neuroleptic agents. Comparatively, patients treated with risperidone experience substantially fewer side effects, including extrapyramidal symptoms, cognitive toxicity, and tardive dyskinesia.
Tune
L E
LE
Division of Geriatric Psychiatry, Wesley Woods Center on Aging, Emory University School of Medicine, Atlanta, GA 30329, USA.
D000368:Aged; D000374:Aggression / Q000187:drug effects / Q000523:psychology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000453:epidemiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003072:Cognition Disorders / Q000139:chemically induced / Q000453:epidemiology; D003704:Dementia / Q000188:drug therapy* / Q000523:psychology; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011595:Psychomotor Agitation / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D018967:Risperidone